I have an appointment with my liver doc October 15th. The ABBVie tx may have been part of discussion and decision process of whether to wait or not? Thanks Isis for sharing this.
Tig said
Sep 28, 2014
That's a very important consideration people have to make and you have to wonder how many are. Unless people have a very savvy doctor that considers this possibility, patients that are anxious to get started may fail to remember the calendar year policy change. It's a valuable reminder you've made, well done!
Tig
Isiscat2011 said
Sep 28, 2014
While we are on the subject, December 21st is precarious timing for some patients, because they may have insurance changes beginning in Jan, 2015. Or, if they are lucky enough to get immediate approval they could be slammed with two deductibles--one for 2014 and another for 2015.
Some things to think about for anyone considering this or any combo where the tx could continue into the next year, or if they are planning to change policies in Jan. On my last tx I got hit with a double deductible because my tx began in November and carried into the following year.
Tig said
Sep 28, 2014
Isiscat2011 wrote:
More like the investors. They love this stuff--it is all a big game--It is about the profits not about people's lives to them.
Bingo! Kind of like "Big Pharmopoly"!!
Tig
Isiscat2011 said
Sep 28, 2014
Tig56 wrote:
I can just see the legal teams scrambling for position!
More like the investors. They love this stuff--it is all a big game--It is about the profits not about people's lives to them.
Isiscat2011 said
Sep 28, 2014
I think the confusion is that the review of the Abbvie combo is being listed in the FDA PDUFA calendar under the Pharma name of ENANTA (ENTA). ENANTA is a pharmaceutical company that formed a partnership with Abbvie and is collaborating on the HCV combo.
The review is scheduled for 12/21/2014 but under the ENANTA name.
http://www.biopharmcatalyst.com/fda-calendar/
Some biotech investors are yapping about it. Bunch of dummies.
Tig said
Sep 28, 2014
I see the the FDA Advisory Committee for 2015 still lists it as:
Antiviral Drugs Advisory Committee
Date(s), if needed, to be determined
It would appear you're right and there has been a delay placed on the decision... Hmmm?
Tig
Tig said
Sep 28, 2014
Where did you hear that report? I'm still finding dated reports mentioning the original decision. I did notice that the decision for approval in the EU is still slated for the first quarter of 2015. I can just see the legal teams scrambling for position!
Tig
Isiscat2011 said
Sep 28, 2014
There is a rumor going around that the Abbvie combo, which was scheduled for FDA review in December of 2014, is no longer on the approval review calendar for this year. I checked the FDA review calendar and it appears to be true.
Anybody know anything about this? A significant development if true.
I have an appointment with my liver doc October 15th. The ABBVie tx may have been part of discussion and decision process of whether to wait or not? Thanks Isis for sharing this.
That's a very important consideration people have to make and you have to wonder how many are. Unless people have a very savvy doctor that considers this possibility, patients that are anxious to get started may fail to remember the calendar year policy change. It's a valuable reminder you've made, well done!
Tig
While we are on the subject, December 21st is precarious timing for some patients, because they may have insurance changes beginning in Jan, 2015. Or, if they are lucky enough to get immediate approval they could be slammed with two deductibles--one for 2014 and another for 2015.
Some things to think about for anyone considering this or any combo where the tx could continue into the next year, or if they are planning to change policies in Jan. On my last tx I got hit with a double deductible because my tx began in November and carried into the following year.
More like the investors. They love this stuff--it is all a big game--It is about the profits not about people's lives to them.
Bingo! Kind of like "Big Pharmopoly"!!
Tig
I think the confusion is that the review of the Abbvie combo is being listed in the FDA PDUFA calendar under the Pharma name of ENANTA (ENTA). ENANTA is a pharmaceutical company that formed a partnership with Abbvie and is collaborating on the HCV combo.
The review is scheduled for 12/21/2014 but under the ENANTA name.
http://www.biopharmcatalyst.com/fda-calendar/
Some biotech investors are yapping about it. Bunch of dummies.
I see the the FDA Advisory Committee for 2015 still lists it as:
It would appear you're right and there has been a delay placed on the decision... Hmmm?
Tig
Where did you hear that report? I'm still finding dated reports mentioning the original decision. I did notice that the decision for approval in the EU is still slated for the first quarter of 2015. I can just see the legal teams scrambling for position!
Tig
There is a rumor going around that the Abbvie combo, which was scheduled for FDA review in December of 2014, is no longer on the approval review calendar for this year. I checked the FDA review calendar and it appears to be true.
Anybody know anything about this? A significant development if true.